ITIF Search

Life Sciences

Innovation is essential to promoting human health, agricultural productivity, and ecological sustainability. ITIF’s Center for Life Sciences Innovation conducts research supporting advances in human biotechnology; pharmaceuticals; and health care policy outside the realm of IT.


How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale

How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale

Stringent drug price controls have significantly hampered the competitive and innovative capacity of Japan’s biopharmaceutical industry in recent decades, serving as a warning for U.S. policymakers considering introducing Medicare Part D drug price controls in 2022.

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Expenditures for retail prescriptions have been roughly stable for the past two decades as a share of total U.S. health-care expenditures. Instead of applying broad price controls, policymakers should promote affordability and mitigate out-of-pocket costs for individuals.

More Publications and Events

April 4, 2023|Events

Lessons From the Rise and Fall of Japan’s Life-Sciences Innovation Ecosystem

Please join ITIF for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

March 24, 2023|Events

Preserving a Virtuous Cycle: The Economics of Biopharmaceutical Innovation

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

March 20, 2023|Reports & Briefings

The Economics of Biopharmaceutical Innovation: Symposium Report

Investments in biopharmaceutical innovation and expenditures on medicines themselves both produce tremendous societal returns. Maintaining the robust innovation ecosystem necessary to capitalize on these benefits requires the right mix of “push” and “pull” incentives.

January 25, 2023|Reports & Briefings

How Off-Label Use of Medicines Drives Health-Care Use and Disability

Peer-reviewed research finds that pharmaceutical innovation provides direct and indirect benefits for health-care use and disability.

December 9, 2022|Blogs

Don’t Delay! Stop the Expanded TRIPS Waiver Today

There is nothing meritorious about an expanded TRIPS waiver for COVID-19 therapeutics and diagnostics IP. Just like the TRIPS waiver for COVID-19 vaccines, the expanded waiver proposal is unnecessary, inappropriate, and harmful. The United States and its allies must not allow it to continue.

October 13, 2022|Presentations

Lessons From Mexico’s Life Sciences Innovation Ecosystem for Indonesia

Stephen Ezell joins the program at HigherHeight 2022, hosted by Pfizer Indonesia and the Indonesian Biotechnology Study Program Association (IPSBI), to discuss what Indonesia can learn from Mexico’s experiences in building up its life sciences innovation ecosystem.

September 16, 2022|Presentations

Innovations and the Future of Healthcare

Stephen Ezell will be speaking at the James Madison Institute’s Florida Tech & Innovation 2022 Summit in Coral Gables, Florida on a panel discussing “Innovations and the Future of Healthcare.”

August 9, 2022|Press Releases

Reconciliation Bill Detrimental for U.S. Life Sciences Innovation, Says ITIF

The Inflation Reduction Act of 2022 incorporates unnecessary and unwarranted drug price controls that will harm America’s life-sciences innovation industry and deter biomedical innovation.

August 5, 2022|Blogs

Senate Reconciliation Legislation Fails to Reconcile the Interests of Biomedical Innovation and Drug Price Affordability

The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.

August 1, 2022|Podcasts

Podcast: Life Sciences Innovation Through the Bayh-Dole Act, With Joe Allen

Rob and Jackie sat down with Joe Allen, who served as a professional staffer on the U.S. Senate Judiciary Committee to former Senator Birch Bayh, to discuss the importance of the Bayh-Dole Act and the future of life sciences innovation.

Back to Top